Analysis of Osteoporosis Treatment Patterns with Bisphosphonates and
Outcomes among Postmenopausal Veterans
J. LaFleur, S.L. DuVall, T. Willson, T. Ginter, O. Patterson, Y. Cheng,
K. Knippenberg, C. Haroldsen, R.A. Adler, J.R. Curtis, I. Agodoa, R.E.
Nelson
PII:
DOI:
Reference:

S8756-3282(15)00135-0
doi: 10.1016/j.bone.2015.04.022
BON 10689

To appear in:

Bone

Received date:
Revised date:
Accepted date:

16 July 2014
24 March 2015
14 April 2015

Please cite this article as: LaFleur J, DuVall SL, Willson T, Ginter T, Patterson O,
Cheng Y, Knippenberg K, Haroldsen C, Adler RA, Curtis JR, Agodoa I, Nelson RE,
Analysis of Osteoporosis Treatment Patterns with Bisphosphonates and Outcomes among
Postmenopausal Veterans, Bone (2015), doi: 10.1016/j.bone.2015.04.022

This is a PDF le of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its nal form. Please note that during the production process
errors may be discovered which could aect the content, and all legal disclaimers that
apply to the journal pertain.

ACCEPTED MANUSCRIPT
ANALYSIS OF OSTEOPOROSIS TREATMENT PATTERNS WITH BISPHOSPHONATES
AND OUTCOMES AMONG POSTMENOPAUSAL VETERANS

PT

LaFleur J1,2, DuVall SL1,2, Willson T1,2, Ginter T2, Patterson O2, Cheng Y1,2, Knippenberg K1, Haroldsen C2,3,
Adler RA4, Curtis JR5, Agodoa I6, Nelson RE2,3

AC
CE
P

TE

Correspondence and requests for reprints:

Joanne LaFleur, PharmD, MSPH
Department of Pharmacotherapy
30 South 2000 East, Room 4765
Salt Lake City, UT 84112
University of Utah
Phone: 801-585-3794
Fax: 801-587-7923
Email: joanne.lafleur@pharm.utah.edu

MA

NU

SC

RI

1. Pharmacotherapy Outcomes Research Center, University of Utah, 30 South 2000 East, Salt Lake
City, Utah 84112
2. VA Salt Lake City Heath Care System, 500 Foothill Drive, Salt Lake City, Utah 84148
3. Department of Internal Medicine, University of Utah, 30 North 1900 East, Salt Lake City, Utah
84132
4. Hunter Holmes McGuire Veterans Affairs Medical Center, 1201 Broad Rock Boulevard,
Richmond, Virginia 23224
5. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1825
University Boulevard, Birmingham, Alabama 35294-2182
6. Amgen, Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320

Abbreviations: BMD = bone mineral density; BMI = body mass index; CDW = corporate data warehouse;
COPD = chronic obstructive pulmonary disease; CPT = Current Procedural Terminology; DSS = decision
support system; GEE = generalized estimating equations; ICD-9 = 9th revision of the International
Classification of Diseases; NLP = natural language processing; OLS = ordinary least squares; PCE =
Personal Consumption Expenditures; PMO = postmenopausal osteoporosis; SSRIs = selective serotonin
reuptake inhibitors; VA = Veterans Affairs; VHA = Veterans Health Administration; VINCI = Veterans
INformatics and Computing Infrastructure; WHO FRAX = World Health Organization absolute Fracture
Risk Assessment Tool.

ACCEPTED MANUSCRIPT
ABSTRACT

PT

Purpose: Adherence and persistence with bisphosphonates are frequently poor, and stopping,
restarting, or switching bisphosphonates is common. We evaluated bisphosphonate change behaviors
(switching, discontinuing, or reinitiating) over time, as well as fractures and costs, among a large,
national cohort of postmenopausal veterans.

NU

SC

RI

Methods: Female veterans ages 50+ treated with bisphosphonates during 2003-2011 were identified in
Veterans Health Administration (VHA) datasets. Bisphosphonate change behaviors were characterized
using pharmacy refill records. Patients' baseline disease severity was characterized based on age, Tscore, and prior fracture. Cox Proportional Hazard analysis was used to evaluate characteristics
associated with discontinuation and the relationship between change behaviors and fracture outcomes.
Generalized estimating equations were used to evaluate the relationship between change behaviors and
cost outcomes.

TE

MA

Results: A total of 35,650 patients met eligibility criteria. Over 6,800 patients (19.1%) were nonswitchers. The remaining patients were in the change cohort; at least half displayed more than one
change behavior over time. A strong, significant predictor of discontinuation was 5 healthcare visits in
the prior year (11-23% more likely to discontinue), and discontinuation risk decreased with increasing
age. No change behaviors were associated with increased fracture risk. Total costs were significantly
higher in patients with change behaviors (4.7-19.7% higher). Change-behavior patients mostly had
significantly lower osteoporosis-related costs than non-switchers (22%-118% lower).

AC
CE
P

Conclusions: Most bisphosphonate patients discontinue treatment at some point, which did not
significantly increase the risk of fracture in this majority non-high risk population. Bisphosphonate
change behaviors were associated with significantly lower osteoporosis costs, but significantly higher
total costs.
Keywords: Osteoporosis, bisphosphonate, treatment patterns, fracture risk, cost, veterans

ACCEPTED MANUSCRIPT
INTRODUCTION

MA

NU

SC

RI

PT

Poor patient adherence and persistence are common with bisphosphonates, which are considered firstline treatments for postmenopausal osteoporosis (PMO). Reasons for poor adherence and persistence
include but are not limited to lack of perceived benefit, lack of understanding, side effects, and
inconvenience.1 In observational studies, the proportions of patients that persisted with therapy for 1
year are low for United States (US) cohorts (21.0-56.7%) and non-US cohorts (21.9-74.8%).2-11 Some
studies have reported an association between low adherence or persistence and fracture outcomes or
healthcare costs (i.e., higher fracture rates or higher costs in patients with lower adherence).8,12-18
However, the effect of changing medications on osteoporosis health outcomes has not been well
characterized. Several studies demonstrate improved persistence or adherence following a treatment
switch,7,19,20 with only one to the contrary.16 We are aware of one study using a small regional cohort
that examined the effect of medication switching on fracture risk. Briesacher and colleagues did not find
a significant effect of medication switching on fracture risk in a small sample of patients who switched
between once weekly and once monthly bisphosphonates.21 Given these controversies and
inconsistencies in the literature, we sought to examine the effect of switching behaviors on fracture risk
and cost outcomes in a large, national cohort of postmenopausal veterans.

AC
CE
P

TE

Few studies have investigated the link between bisphosphonate medication-taking behavior and
osteoporosis-related outcomes while controlling for baseline disease severity. One study restricted
analysis to patients with a bone mineral density (BMD) T-score -2.5 and/or a prior vertebral fracture.14
However, no studies adjusted for baseline BMD in an effort to isolate the independent effect of
adherence on outcomes in patients across a range of osteoporosis severity. This is, perhaps, because
most studies that use administrative claims datasets typically do not contain clinical data.11,14-17,20
However, even studies conducted in datasets containing some clinical data8,13 still lacked the ability to
capture BMD in structured data, making adjustment for baseline disease severity challenging.
To our knowledge, no research has been done to describe bisphosphonate use and outcomes in the
female veteran PMO population while controlling for severity. Studies conducted in the Veterans Health
Administration (VHA) are usually overwhelmingly male,22,23 and osteoporosis studies have been no
exception.24,25 Thus, in the bisphosphonate-treated PMO population in the VHA, we sought to
characterize bisphosphonate switching patterns; to identify patient and disease characteristics that
were associated with switching or discontinuation behaviors; and to investigate the possible relationship
between patient medication-taking behaviors and outcomes, including cost and fracture events. As a
methodological improvement on past observational analyses and a unique feature of our investigation,
we used natural language processing (NLP; a computerized algorithm with which certain data or
concepts in an electronic text record are identified) to extract information on BMD and other clinical risk
factors for fracture from radiology reports and clinic notes. This information was used to control for
baseline disease severity.26-28

METHODS
Study design and datasets
In this cohort study, we used historical data from several VHA datasets hosted in the VINCI (Veterans
INformatics and Computing Infrastructure) environment, linking across datasets with the VHAs unique
scrambled social security number system. Datasets included the VHAs Decision Support System (DSS)
dataset, from which we identified bisphosphonate fills, other medications, and cost information for

ACCEPTED MANUSCRIPT

PT

pharmacy, inpatient, outpatient, radiology, and laboratory services; the VHAs Medical SAS dataset,
from which we identified age, race/ethnicity, and fracture outcomes; the Corporate Data Warehouse
(CDW) dataset, from which we identified vital signs (height and weight for body mass index [BMI]
calculation) and narrative records (the clinician progress notes and radiology reports that we used to
extract BMD T-scores and other clinical risk factors for fracture).
Natural language processing (NLP)

SC

RI

We used NLP technology to identify several risk factors from narrative text including radiology reports
(for BMD) and clinic notes (for BMD, smoking, alcohol consumption, and family/maternal history of
osteoporosis or fracture). Separate, narrow-focused NLP applications were built for each of these four
variables.

NU

Smoking status was extracted using a system previously developed and validated on the VA clinical
notes.27

TE

MA

Applications to extract the other three variables were built following an iterative system development
model, in which a system is built incrementally in phases called iterations. Each iteration consists of
planning, development, and error analysis phases. For the current system at each iteration, a set of
manually developed rules was built or expanded aiming to detect relevant concepts, their context, and
relationships. Iterations involve rigorous error checking to compare system output to manual
annotations. The error analysis findings inform the next iteration. The measure of the system
performance improvement is estimated by relative decrease in the error rate between iterations. When
the error rate improvement falls bellow 1% it is determined to have reached a plateau and the
development cycle is determined to be complete.29

AC
CE
P

Final performance of these applications was manually validated on a randomly selected set of notes for
each involved variable separately. For example, for the T-score application, a random sample of 1,000
instances was reviewed to assess the accuracy of the tool for extracting T-score, anatomy (e.g.,
anatomic sites mentioned in proximity to the T-score such as lumbar spine or femoral neck), and the
association between anatomy and T-score (i.e., that a given site was related in the note to a particular
anatomic site, such as a femoral neck BMD T-score versus a lumbar spine BMD T-score). The mean
accuracy (number of correct extractions divided by the total number of extractions) of the BMD
extraction tool was 82.8% for T-score, 92.6% for anatomic site, and 82.8% for the correct BMD being
associated with the correct anatomic site. For smoking, alcohol use, and family/maternal history of
osteoporosis or fracture, the mean accuracies were 83.4%, 75.9%, and 76.3%, respectively. 26,27
Previous approaches to acquiring variables for family/maternal history of osteoporosis and BMD scores
have used administrative data, personal interviews or questionnaires, manual chart review, 30-33 and
prospective measurement. 34 As such, they have been limited to smaller cohorts of patients. Several
studies have used NLP to identify family history of other medical conditions or distinguish between
family history and personal history, with accuracies ranging from 81.3% to 93.8%.35-37 Although this
range is slightly higher than reported here, each of these studies used only 1 to 2 document types from
1 to 2 hospitals, in which document sections could be specifically identified. Data for our study came
from thousands of document types from more than 1,400 points of care (medical centers, clinics,
nursing homes, and long-care facilities) all across the US.
Alcohol consumption is also usually recorded through interviews, questionnaires, or manual chart
reviews.38-40 Extraction of alcohol consumption status has been attempted using NLP before, with

ACCEPTED MANUSCRIPT
accuracy of 89.4%. 41 The authors admit that such a high level of accuracy is partially attributable to the
high level of consistency in the clinical notes in the sample the same physician dictated them all.

PT

Smoking status has been classified using NLP in several studies, ranging from 23% to 81%. 42 Our system
performance is comparable to these previous systems.
Patients

AC
CE
P

TE

MA

NU

SC

RI

We identified a national cohort of female veterans aged 50 years and older who had an outpatient
encounter and who received an osteoporosis bisphosphonate prescription (oral alendronate, oral or
injectable ibandronate, oral risedronate, or injectable zoledronic acid) during the study period (January
1, 2003-December 31, 2011). All patients with an outpatient encounter during the study period and then
a bisphosphonate prescription at least 6 months later but still within the study period (i.e., the index
prescription) were eligible for analysis and were classified as incident or prevalent bisphosphonate users.
The index date was defined, not as the first bisphosphonate prescription filled during the study period,
but as the first bisphosphonate prescription filled at least 6 months after the first VHA outpatient
encounter in the study period. Prevalent bisphosphonate users were those with any bisphosphonate
prescription between the beginning of the study period (January 1, 2003) and the index bisphosphonate
prescription. Incident bisphosphonate users were those with no bisphosphonate use of any kind from
the beginning of the study period (January 1, 2003) up to the index bisphosphonate prescription (the
first prescription at least 6 months after the first outpatient encounter). For example, a patient may
already be taking a bisphosphonate when the study period begins, and may continue on that
bisphosphonate, but her index date/prescription would not occur until 6 months after her first VHA
outpatient encounter during the study period. This patient would be a prevalent user. In the fracture
analyses, patients were censored upon the first fracture after the index bisphosphonate or, for those
who did not fracture, on their last encounter in the VA system.
Patients were excluded if they had one or more of the exclusionary diseases, defined as having at least 2
codes from the 9th revision of the International Classification of Diseases (ICD-9) for a condition on two
separate occasions at any time prior to the index date. Exclusionary diseases included Pagets disease,
osteogenesis imperfecta, hypercalcemia, malignant cancer, or human immunodeficiency virus infection
(HIV; see Supplemental Table 1 for specific ICD-9 codes). To avoid selection bias (because of conditioning
study inclusion on an event that occurs after the index date), patients who had a second exclusionary
diagnosis after the index date contributed person-time only until the date of the second exclusionary
diagnosis and then were censored. Patients were also excluded if their index bisphosphonate was for a
dose or dosage form that is primarily used for Pagets disease (e.g., alendronate 40 mg daily or
risedronate 30 mg daily).
This Health Insurance Portability and Accountability Act (HIPAA)-compliant study was approved by the
University of Utah Institutional Review Board (IRB) and the Salt Lake City VHA Research and
Development office.
Definitions
Baseline patient characteristics
Baseline patient characteristics in the 6 month period before the index prescription included
demographics (age, race/ethnicity, BMI, marital status, smoking status, alcohol history, and healthcare
visit frequency for prior year); osteoporosis disease characteristics (10-year hip fracture probability and
10-year major osteoporosis-related fracture probability based on the US-adapted World Health

ACCEPTED MANUSCRIPT

RI

PT

Organization [WHO] absolute Fracture Risk Assessment Tool [FRAX], an actionable score being >3% for
hip fracture or >20% for any major fracture), BMD T-score, history of prior fracture, family/maternal
history of osteoporosis or fracture, and index bisphosphonate use); comorbidities (diabetes, dementia,
chronic obstructive pulmonary disease [COPD], and depression); and drug exposures (calcitonin, calcium,
heparin, hormone replacement therapy, lithium, proton pump inhibitors, raloxifene, seizure medications,
benzodiazepines, opioids, selective serotonin reuptake inhibitors [SSRIs], statins, teriparatide, thiazide
diuretics, thyroid medications, and vitamin D). In the case of multiple readings of the same characteristic,
we always used the one closest to the index date as "baseline." Patients were classified as high risk or
low risk as described below (see the Baseline disease severity section).

SC

Baseline disease severity

TE

MA

NU

Patients baseline disease status was classified as high risk if they met any 2 of the following 3
conditions: (1) femoral neck BMD T-score -2.5,43,44 (2) age 70 and BMD T-score of the total hip, spine,
or one-third radius -2.5;43-45 or (3) prior fracture at the hip, spine, forearm, humerus, pelvis, or
tibia/fibula at any time.46 These particular fracture sites were chosen not only because the WHO FRAX
uses them, but also because they are documented in the literature as the most common sites for
osteoporotic fractures. 47 Some baseline patient characteristics were used as inputs for the WHO FRAX
absolute fracture risk calculator,48 including race/ethnicity, age, weight, height, prior major fracture,
family/maternal history of fracture, current smoking, corticosteroid use, rheumatoid arthritis diagnosis,
a diagnosis related to secondary osteoporosis, and alcohol exposure. These fields were extracted from
structured data or via NLP where structured data were not available (i.e., BMD, family/maternal history
of osteoporosis or fracture, current smoking status as of the index date, and alcohol consumption).
Bisphosphonate change behavior definitions

AC
CE
P

Patient bisphosphonate change behaviors over time were characterized as non-switching, switching,
discontinuing, and reinitiating. Non-switching was defined as continuing on the index bisphosphonate
for the duration of follow-up (until censoring), switching was defined as switching from the index
bisphosphonate to a different bisphosphonate (e.g., alendronate to risedronate), discontinuing was
defined as having stopped treatment for a gap length of at least 90 days after the end of the prior days
supply, and reinitiating was defined as restarting the index bisphosphonate after a prior discontinuation
or switch. Zoledronic acid, administered once per calendar year, was also subject to the 90-day rule. We
selected a 90-day gap length for classifying a discontinuation event to be conservative in classification;
however, we evaluated alternate gap lengths of 30 and 60 days in sensitivity analyses. All patients were
considered to be non-switchers on the index date and their change behavior status was updated every
90 days depending on their change behavior in the prior 90-day quarter. For patients with multiple
change behaviors in the same quarter, the patients exposure was updated to correspond to the most
recent change.
Fracture outcomes
We conducted analyses for two fracture outcomes (hip fracture and any major fracture, [i.e., hip, spine,
forearm, or humerus]) and a composite outcome (fracture of the hip, forearm, clinical spine, or
humerus) to occur during 2003-2011. Fractures were identified using ICD-9 codes (see Supplemental
Table 1). Since a recent publication demonstrated a consensus among clinicians that most fractures in
patients over age 50 are osteoporosis-related,47 we included all fractures of the above skeletal sites,
regardless of whether they occurred in the context of a trauma code.

ACCEPTED MANUSCRIPT
Cost outcomes

SC

RI

PT

We calculated total costs and osteoporosis-related costs during 2003-2011 by summing costs associated
with inpatient and outpatient encounters from the DSS dataset. DSS contains records for office visits,
pharmacy services, laboratory testing, and radiology. The definitions of inpatient and outpatient
were based entirely on structured data. Inpatient costs were found in the Inpatient table of the DSS
dataset, with separate variables for nursing, lab, radiology, surgery, prescription, and other costs. The
Outpatient table of the DSS dataset contained outpatient costs. Osteoporosis costs were calculated by
including only those cost observations that were associated with a primary ICD-9 code for osteoporosis
or fracture, Current Procedural Terminology (CPT) codes for bone density scans, or a pharmacy record
for an osteoporosis-related treatment (oral alendronate, oral risedronate, oral or injectable ibandronate,
or injectable zoledronic acid; see Supplemental Table 1). All costs were converted to 2011 US dollars
using the Personal Consumption Expenditures (PCE) Index from the Bureau of Economic Analysis.

NU

Statistical analysis

Patient characteristics, overall and by change behavior

MA

Descriptive statistics, including means and standard deviations (SD) for continuous variables and
frequencies and proportions for categorical variables, were calculated. We calculated descriptive
statistics for baseline characteristics for all patients, patients with bisphosphonate change behaviors,
and patients without bisphosphonate change behaviors. Descriptive statistics were also used to
characterize the proportions with change behaviors in the follow-up period.

TE

Predicting the effect of patient characteristics on bisphosphonate discontinuation

AC
CE
P

To identify predictors of bisphosphonate discontinuation (defined as the occurrence of a 90-day gap

following the end of a prior days supply), a multivariable Cox Proportional Hazards regression model
was constructed to examine the relationship between baseline patient characteristics and
discontinuation. To identify independent predictors of discontinuation, we used a backward stepwise
selection procedure, eliminating variables one at a time if p0.1, which is the common p-value used in
backwards stepwise selection. Patients were censored at the last encounter with the VHA system in the
study period. Sensitivity analyses were conducted for alternate gap lengths of 30 and 60 days using the
same methods.
Predicting the effect of bisphosphonate change behaviors on fracture, with sensitivity analyses
A series of multivariable Cox Proportional Hazards regression models was constructed to examine the
relationship between bisphosphonate change behaviors and fracture events, one for overall and one
each for high-risk and not high-risk patients. To identify the least biased effect measure for the
association between each change behavior and fracture events, our regression models included as
covariates all observable variables with a known or theoretical relationship to fracture and bone quality:
patient characteristics (age, marital status, race), utilization traits (visits in the prior year), index
bisphosphonate (alendronate, ibandronate, risedronate, zoledronic acid), and FRAX risk factors (alcohol
use, smoking status, BMI, prior fracture by site, rheumatoid arthritis diagnosis, diagnosis of conditions
related to secondary osteoporosis, and steroid exposure). We also adjusted for baseline diagnoses of
COPD and depression and baseline drug exposures thought to be associated with fracture risk (calcium,
vitamin D, calcitonin, heparin, hormone therapy, lithium, proton pump inhibitors, raloxifene,
benzodiazepines, opioids, selective serotonin reuptake inhibitors, statins, and thyroid medications). The
bisphosphonate change behavior variable was treated as time-varying and was the only time-varying

ACCEPTED MANUSCRIPT
independent variable included in the models. The unit of analysis for these regression models was a 90day person-quarter. The exposure was lagged by one quarter to avoid the scenario in which a fracture
event is attributed to a change that occurred later in the same quarter. However, an unlagged sensitivity
analysis was also conducted.

MA

NU

SC

RI

PT

In our primary analysis, we defined the medication change behavior variable in each quarter as a current,
momentary point in time based on the most recent behavior (non-switching, switching, discontinuing,
reinitiating) in the previous 90 days. However, because the effects of bisphosphonates are thought to
take 1-2 years,49 we also performed 2 sensitivity analyses that varied how the bisphosphonate change
behavior variable was defined. In the first sensitivity analysis, we treated the bisphosphonate exposures
as cumulative rather than momentary; discontinuation was defined as the cumulative proportion of
person-time during which the patient was classified as a discontinuer and updated each quarter, and
switching was defined as the cumulative count of switches the patient had made since the index date,
also updated quarterly. In the second sensitivity analysis, we used only patients with at least 1 year of
observation and for whom there were no changes in the first year. In this model, follow-up started at
the 1-year mark, so as to model the onset of effect of bisphosphonate therapy. In all models, the
dependent variable was the time to a dichotomous fracture event. Multivariable Cox Proportional
Hazards regression models were also used for sensitivity analyses.
Effect of change behaviors on cost

AC
CE
P

TE

Many patients have no healthcare use while a few outliers have very high healthcare costs; therefore,
the assumption required for ordinary least squares (OLS) regression to yield unbiased results is violated
in the association between change behaviors and cost outcomes.50 Several alternative statistical models
have been proposed to overcome this problem,50 and we used model fit tests to determine the most
appropriate distribution for our data.51 To obtain the least biased estimate of the effect of change
behaviors on cost, we adjusted for all the important covariates listed above, plus total cost in the prior 6
months, and ran three models: one for all patients and one each for high-risk and not high-risk patients.
Because each patient in the analysis cohort had the potential for multiple observations (one for each
quarter of data), we used generalized estimating equations (GEE) to adjust for the clustering of
observations within patients.52 For these GEE models, we assumed a gamma distributed dependent
variable with a log link. Similar to the fracture analyses, the dependent variables in the cost regressions
were lagged forward one quarter to allow us to estimate the impact of a change behavior on
expenditures in the subsequent quarter, all of which will have occurred after the change behavior
occurred. 53,54 We ran separate models for each outcome: total costs, osteoporosis-related costs, and
osteoporosis-related pharmacy costs (see Cost outcomes, above) for overall patients, high-risk patients,
and not high-risk patients.

RESULTS
Patients
As shown in Figure 1, out of more than 1.6 million female veterans age 50+ with an outpatient
encounter in 2003-2011, 43,543 (2.6%) had a prescription for a bisphosphonate and 35,650 (2.2%) met
all eligibility criteria and were included in the study. The majority of included patients (90.7%) were
incident bisphosphonate users; only a small minority (9.3%) comprised prevalent users. Characteristics
of the cohort are summarized in Table 1. The mean (SD) age was 65.7 (12.5), BMI was 27.2 (6.1), and
BMD T-score (at the hip, spine, femur, or 1/3 radius) was -1.58 (1.75). Only 63.2% of patients had Tscores available; of these, the majority was in the low bone mass range (T-score of -1.0 to -2.5; 48.3%).

ACCEPTED MANUSCRIPT

PT

Among the 85% of patients in whom FRAX scores could be calculated, the majority exceeded the
National Osteoporosis Foundation (NOF)-recommended FRAX risk thresholds of 3% for hip fracture
(54.2% of the cohort) or 20% for any major fracture (69.6% of the cohort), for whom pharmacologic
treatment is recommended. Overall, mean (SD) observation time until fracture events was 52.8 (27.9)
months. The minimum and maximum were 0.03 and 102 months, respectively.
Bisphosphonate change behaviors

NU

SC

RI

As shown in Figure 2, only 6,804 patients (19.1%) persisted on their index bisphosphonate and thus
were counted as non-switchers over a median follow-up period of 4 years and 95 days (i.e., 1556 days).
Among the 28,846 patients (80.9%) who exhibited change behaviors, 2,610 (7.3%) switched to a
different bisphosphonate, 28,622 (80.3%) discontinued, and 14,452 (40.5%) reinitiated at least once
during the follow-up period. At least half of all patients in the change behavior subcohort displayed
more than one type of change over time. Among discontinuers, the median time to first discontinuation
was 294 days and the median duration of the first discontinuation gap was 159 days from the end of the
prior days supply.

MA

Predictors of bisphosphonate discontinuation

AC
CE
P

TE

Table 2 shows the patient characteristics that remained significant predictors of bisphosphonate
discontinuation at p<0.1. The strongest predictors were a higher number of healthcare visits in the prior
year, which increased discontinuation risk 11-23% compared to patients with fewer than 5 visits; and
Black and Hispanic race/ethnicity, which were associated with 17% and 21% increased risks of
discontinuation compared to Caucasians. Having zoledronic acid as the index bisphosphonate was
associated with a markedly decreased risk of discontinuation (only 58% of the risk for alendronate), and
increasing age was associated with a 9-22% lower discontinuation risk, compared to a patient younger
than age 55.
Effect of bisphosphonate change behaviors on fracture outcomes
Crude incidence of any major fracture occurred at a rate of 15.9 events per 1000 person-years overall.
The non-switching subcohort had an incidence of 16.9 events per 1000 person-years, and the
discontinuing subcohort and reinitiating subcohort incidences were 15.7 and 16.7 events per 1000
person-years, respectively. The switching subcohort's incidence was 20.5 events per 1000 person-years.
The differences among these groups were not significant.
Crude incidence of hip fracture occurred at a rate of 3.0 events per 1000 person-years overall. The
change behavior subcohort with the highest incidence of hip fracture was the switching subcohort, at
3.7 events per 1000 person-years. This was followed by the reinitiating and discontinuing subcohorts, at
3.2 and 2.9, respectively. The non-switching subcohort had 3.2 events per 1000 person-years. The
differences across change behavior sub-cohorts were not statistically significant.
In the multivariable analyses, which adjusted for patient characteristics, utilization visits in the prior
year, index bisphosphonate, FRAX risk factors (alcohol use, smoking status, BMI, prior fracture by site,
rheumatoid arthritis diagnosis, diagnosis of conditions related to secondary osteoporosis, and steroid
exposure), baseline diagnoses of COPD and depression, and baseline drug exposures thought to be
associated with fracture risk, no statistically significant differences in hip or any major fracture events
among the compared groups were identified for any of the change behavior groups compared to nonswitchers in either the primary or sensitivity analyses (Figure 3). Findings in sensitivity analyses were no
different for gap lengths of 30 or 60 days or for the unlagged exposure.

ACCEPTED MANUSCRIPT
Cost outcomes

PT

Total costs for the cohort over the study period were $1.48 billion, with inpatient costs totaling $395
million and outpatient costs accounting for $1.08 billion. Total osteoporosis-related costs over the study
period were $44.7 million. Of this, inpatient costs were $11.6 million, outpatient costs were $12.7
million, and pharmacy costs were $20.4 million.

SC

RI

Accounting for variable patient follow-up time, mean annual total costs per patient were $10,291 (with
outpatient costs being $7,070 and inpatient costs being $3,221) per patient. Of this, mean annual
osteoporosis-related costs were $320, and of this, mean annual osteoporosis-related inpatient costs
were $96 and mean annual osteoporosis-related outpatient costs were $83. The greatest contributor to
osteoporosis-related costs was prescription drugs, with a mean annual cost of $140.

TE

MA

NU

The adjusted quarterly total, osteoporosis-related, and osteoporosis-related pharmacy cost differences
associated with change behaviors compared to the non-switching subcohort are shown in Table 3. The
coefficients presented in this table represent the percentage change in quarterly cost associated with
the change behavior relative to being a non-switcher; the quarterly differences are also given in dollars.
The total costs were significantly higher for all change behavior subcohorts (p 0.02) except for the highrisk switchers. In terms of magnitude, the greatest differences in total cost can be seen in the reinitiating
subcohort, which was 20% higher for high-risk, 16% higher for not high-risk, and 17% higher overall;
these differences corresponded to quarterly total cost differences of $637, $343, and $394, respectively.
Total cost differences for switchers ranged from 13-14%, a cost difference of $294-494; the total cost
differences for discontinuers ranged from only 5-8%, a cost difference of $102-268.

AC
CE
P

In contrast to total costs, patients with change behaviors had significantly lower osteoporosis-related
costs compared to non-switchers. In terms of magnitude, the greatest percentage differences were seen
in the discontinuing cohort, which was 63% lower for high-risk and 118% lower for not high-risk
switchers (106% lower overall). However, although the magnitudes of these differences were large
(versus those seen for total costs), in terms of dollars, these differences were quite small: $76 lower for
high-risk and $74 lower for not high-risk discontinuers ($77 overall). For switchers and re-initiators,
these differences were even smaller: the percentage differences in osteoporosis-related costs among
reinitiators ranged from 17-24%, which corresponded to a $15-21 lower quarterly cost. For switchers,
percentage differences ranged from a 14% lower cost to a non-significant 30% higher cost, or a range
from a $10 quarterly decrease to a non-significant $36 quarterly increase.
Like osteoporosis-related costs, the osteoporosis-related pharmacy costs were all significantly lower in
the change behavior subcohorts compared to the non-switching subcohort. The discontinuing subcohort
had between 220% and 236% lower osteoporosis-related pharmacy costs than the non-switching
subcohort; this corresponded to a $75 lower quarterly osteoporosis pharmacy cost. Costs for switchers
were between 61-67% lower compared to non-switchers, corresponding to a $21 lower quarterly
osteoporosis pharmacy cost. For re-initiators, the quarterly cost differences ranged from 58-60%, or
$19-20 lower cost per quarter.

DISCUSSION
In this study of veterans with PMO, we examined bisphosphonate change behaviors discontinuing,
switching, and reinitiating bisphosphonates and their association with fracture and cost outcomes.
Discontinuation was by far the most common of the change behaviors, with more than 80% having at
least one discontinuation in the first 2.5 years of treatment. The strongest risk factors for
discontinuation were Hispanic race and having a high number of healthcare visits in the prior year.
10

ACCEPTED MANUSCRIPT

PT

However, these risk increases were modest, less than 23%. One recently published study by Yun et al.55
reported modestly increased risk (less than 15%) for Hispanic patients as well as patients with 10+
healthcare visits per year, among other risk factors, in a database cohort study of Medicaid patients.
These differences in adherence associated with race/ethnicity may be the result of differences in
socioeconomic characteristics of patients. Although the VAs coverage of prescription drugs is quite
robust and consistent across the country, the low-cost copay for a 3-month supply might still be a
hardship for people with very low incomes.

NU

SC

RI

Notably, having zoledronic acid as an index bisphosphonate reduced the risk of discontinuation
substantially compared to alendronate, suggesting that less frequent dosing dramatically improves
persistence because patients are not at risk for discontinuation for much of the follow-up time. Curtis et
al. estimate real-world zoledronic acid adherence to be 20% greater than for IV ibandronate, which is
dosed quarterly, and also higher than other studies reporting adherence to weekly or monthly oral
bisphosphonates.56

TE

MA

The subcohort with the highest incidence of both fracture types was the switching subcohort; however,
after multivariable adjustment for potential confounders, the risk differences between the nonswitching cohort and the change subcohorts were no longer significant. This suggests that most of the
difference in risk is driven by patient disease severity, and that more severe patients are more likely to
switch. The subcohort that most closely approached the trend of increased risk with inconsistent
bisphosphonate use was patients at high risk for hip fracture. Switchers, discontinuers, and reinitiators
with a baseline high-risk for hip fracture showed increased (adjusted) risks of 28%, 26%, and 44%,
respectively (see Figure3b), though not statistically significantly so. Indeed, the 44% increased risk for
reinitiators in the high-risk group may be a reassuring sign that clinicians are identifying high-risk
patients and are pressuring them to restart their bisphosphonates after discontinuing them.

AC
CE
P

For cost outcomes, quarterly total healthcare costs were higher in most change behavior subcohorts
compared to those who did not change, increases that ranged from $102 to $637 per patient per
quarter. In contrast, and given that we did not find higher fracture-related risks and costs in the change
subcohorts, osteoporosis-related total costs were all significantly lower in the change subcohorts;
however, in terms of dollars, these savings were modest (ranging from $10-77 per patient per quarter).
The savings in osteoporosis-related costs among change subcohorts appeared to be entirely driven by
lower osteoporosis-related pharmacy costs; osteoporosis-related pharmacy costs were $19-75 lower per
patient per quarter in the change subcohorts compared to non-switchers. Although the numbers seem
small, particularly the mean annual osteoporosis-related inpatient costs, it is important to realize that
these averages are over the whole cohort, including patients who did not have any inpatient costs at all.
For example, out of 35,650 patients in the cohort, only 420 (1.2%) had osteoporosis-related inpatient
costs; the average in just that subset was $8153. It should also be noted that the large number of
discontinuers in the change cohort likely drives the lower osteoporosis-related pharmacy costs.
However, when you look at the other change subcohorts (i.e., switchers and reinitiators), costs go down
significantly only in patients who were not high-risk. This may be explained by the overlap of these two
subcohorts with the discontinuing subcohort; in the clinical setting, there may be less urgency to keep
patients who do not present as high-risk on bisphosphonates.
Our results confirm what many other researchers have found: patient adherence to bisphosphonates is
poor. We found that 80% discontinued their bisphosphonate medications long before they had
completed 5 years of treatment. Similar estimates of discontinuation after 1 year of therapy from other
US studies have ranged from 43.3% to 83.8%.2-4,6 These results indicate that optimizing osteoporosis
treatment adherence should be a high priority for the clinical community, and while it may result in

11

ACCEPTED MANUSCRIPT

PT

increased pharmacy costs, it should be associated with lower total healthcare costs overall. Chronic
conditions necessitating persistent preventive medication against future outcome are some of the most
difficult conditions to treat, not least because patient compliance tends to drop off over time.57 Likely
the preventive care nature of bisphosphonates reduces the patient's perception of its importance: if
nothing happens (i.e., no fracture), then the bisphosphonate may be working, but the patient is unlikely
to perceive such. This effect can be compounded if the patient suffers from one of the more immediate
side effects of bisphosphonates, such as gastric distress.5

AC
CE
P

TE

MA

NU

SC

RI

Although switching had a higher incidence of subsequent fracture compared to discontinuing in our data,
it was not statistically significantly associated. Switching bisphosphonates was much less common than
discontinuing altogether or restarting the index bisphosphonate. A finding of increased risk associated
with switching relative to discontinuing does not align with published literature. Briesacher and
colleagues similarly did not find a significant effect on fracture risk in patients who switched from once
weekly to once monthly bisphosphonates,21 and others found that switching bisphosphonates improved
persistence overall, which would be expected to reduce fracture risk.7,19,20 Our data also suggest that
medication-taking patterns, even discontinuation, do not significantly impact fracture risk, which does
not correspond to what others have found.8,12-18,58 We can propose reasons for our inability to detect a
relationship between bisphosphonate discontinuations and fracture risk. One is the low proportion of
patients who were non-switchers: only 19%. Considering that only a small percentage of these nonswitchers fractured (4.2%), our study was likely underpowered for detecting differences. Relatedly, a
significant number of fractures may have not been recorded because many fractures are treated outside
the VA.59,60 Existing research is not illustrative, even stratifying by gap length in the definition of
discontinuation (3 months to 7 days).8,12-15,18 Notably, most of these studies also used medication
possession ratio (MPR), 8,12,14,15,18 which Curtis17 shows may inflate the difference between the adherent
and non-adherent. Finally, most (approximately 85%) of women were not at high risk for fracture at
baseline, which may also explain why adherence did not seem to reduce fractures. Our study covers a
time period when many relatively young women with osteopenia being given bisphosphonates.
Study limitations

This study is subject to a few limitations. First, like all observational studies, our findings are potentially
confounded by unmeasured characteristics, despite our best efforts to control for those that were
available in our data. These unmeasured characteristics include subsequent incident events---such as
new incident prescriptions, new incident diagnoses, or other medical or surgical interventions during the
observation period---that might have affected bisphosphonate persistence. Given the long observation
period, all these factors might eventually affect treatment behavior. Second, our inclusion of zoledronic
acid, ensuring 100% persistence for 1 year per dose compared to daily, weekly, or monthly
bisphosphonates, may have skewed annual persistence (though zoledronic acid is not shown to improve
persistence over multiple years/doses 61,62) and reduced the sensitivity of our 90-day discontinuation
gap length to detect changes in bisphosphonate use. However, the 30- and 60-day gap length sensitivity
analyses both indicated that our results are robust. Third, there may be some misclassification of
outcomes or exposures, particularly if patients received care outside the VHA system. We tried to
minimize this by restricting the analysis to patients who showed a pattern of getting their routine care
from within the VHA. For example, since some emergent fractures are more likely to be treated at the
nearest facility, rather than at the patients primary facility, there is a high likelihood that many patients
had fractures that were treated outside the VHA. Nelson et al. documented that only 13% of dualeligible Medicare/VHA patients who fracture are treated in the VHA, based largely on distance from the
VHA facility. 63 Veterans living in rural settings are reported to have lower healthcare utilization and
quality of life, 64,65 which may in turn impact the baseline health state under which fracture events occur.
12

ACCEPTED MANUSCRIPT

NU

SC

RI

PT

However, a study by MacKenzie et al. reported mixed results in elderly veterans, suggesting
socioeconomic factors rather than rurality as a greater driver of overall mortality. 66 It is unknown how
VHA/Medicare utilization may or may not mediate fracture occurrence in our cohort. Our fracture
incidence rates were also 1/3-2/3 lower than would be expected based on clinical trial data in an at-risk
population,67 although the low fracture rate may also be explained by the fact that only 15% of all
women in our study were classified as high-risk, and less than one-quarter were >80 years old. With
regards to the exposure, the inexpensive prescriptions and mail-order prescription service in the VHA
provide an incentive for veterans to receive their refills from VHA pharmacies. However, recent changes
in the retail market with respect to inexpensive generics may promote non-system use. Fourth, we may
also have inadequate characterization of patient baseline risk level. We only had BMD T-scores from
notes and radiology reports in 63% of the sample. For patients who received their BMD screening at a
non-VA facility, then that report may have been kept in the medical record as an image file, which was
not available to us for processing. Thus, if the clinician did not subsequently mention DEXA results in
his/her clinic note, then that would explain the high percentage of missing BMD T-scores.

TE

CONCLUSIONS

MA

Future work should examine the impact of Medicare eligibility on male osteoporosis screening and
treatment patterns in the VHA. It should attempt to detect nuances among the various bisphosphonate
users (e.g., the difference between patients who restart bisphosphonates after a discontinuation and
patients who discontinue bisphosphonates altogether). It should also attempt to predict
bisphosphonate usage patterns, with disease severity (i.e., high-risk and low-risk) as the main
independent variable. Finally, it should also explore the reasons for changing bisphosphonates, which
may be due in large part to adverse effects.

AC
CE
P

This study suggests that real-world variations in adherence and persistence during the long-term
treatment of osteoporosis are common. Our data show that most patients who use bisphosphonates
discontinue them within 30 months, many sooner. However, patients who discontinued or switched
were not at significantly higher risk for fracture compared to non-switchers when controlling for disease
severity, which may be explained by the low proportion of high-risk patients in our cohort. Therefore,
results should be interpreted as applying primarily to low-risk patients. Total costs were higher in
patients with change behaviors. While osteoporosis costs were lower in patients with change behaviors,
the magnitudes of the reductions were small and appeared to be primarily driven by the smaller
pharmacy costs. Furthermore, getting a patient on an individually optimal bisphosphonate, even if it
results in switches and discontinuations, may result in lower osteoporosis-related costs in the long term.

ACKNOWLEDGMENTS
This material is the result of work supported with resources and the use of facilities at the George E.
Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah. The views expressed in this
article are those of the authors and do not necessarily reflect the position or policy of the Department of
Veterans Affairs or the United States government. This research was funded by a grant from Amgen Inc.
The authors would like to thank the Agency for Healthcare Research and Quality (Grant #K08-HS01858201) for their support of Dr. LaFleur during the writing of this manuscript. The authors would also like to
thank Joice Huang and Brad Stolshek for their contributions to the initial research idea.

13

ACCEPTED MANUSCRIPT
REFERENCES

6.
7.

8.
9.
10.

11.

12.

13.

14.
15.

16.

17.

PT

RI

SC

NU

5.

MA

4.

3.

TE

2.

International Osteoporosis Foundation. The Adherence Gap: Why Osteoporosis Patients Don't
Continue with Treatment. Nyon, Switzerland: International Osteoporosis Foundation;2005.
Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with
bisphosphonate dosing regimens among women with postmenopausal osteoporosis*. Current
Medical Research and Opinion. 2005;21(9):1453-1460.
Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses
of orally administered bisphosphonates. Endocr Pract. 2006;12(5):522-528.
Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated
with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J.
2006;99(6):570-575.
Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with
bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther.
2006;28(2):236-242.
Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal
osteoporosis. Osteoporos Int. 2006;17(11):1645-1652.
Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y. Persistence with bisphosphonate therapy including
treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int.
2007;18(10):1421-1427.
Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and
compliance with oral bisphosphonates. J Bone Miner Res. 2008;23(10):1569-1575.
Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral
bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21(1):145-155.
Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM.
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
Osteoporos Int. 2012;23(3):1075-1082.
Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective
cohort analysis on compliance and persistence and the associated risk of fractures in
osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223-231.
Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in
osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims
databases. Mayo Clin Proc. 2006;81(8):1013-1022.
van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM.
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a
database analysis study. Curr Med Res Opin. 2006;22(9):1757-1764.
Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture
risk in osteoporotic women. Osteoporos Int. 2008;19(6):811-818.
Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate
discontinuation: implications for a drug holiday. Osteoporosis International. 2008;19(11):16131620.
Martin KE, Yu J, Campbell HE, Abarca J, White TJ. Analysis of the comparative effectiveness of 3
oral bisphosphonates in a large managed care organization: adherence, fracture rates, and allcause cost. J Manag Care Pharm. 2011;17(8):596-609.
Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with
bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new

AC
CE
P

1.

14

ACCEPTED MANUSCRIPT

23.
24.

25.
26.

27.

28.

29.
30.
31.

32.
33.

PT

RI

SC

NU

22.

MA

21.

20.

TE

19.

AC
CE
P

18.

bisphosphonate users. Journal of bone and mineral research : the official journal of the American
Society for Bone and Mineral Research. 2008;23(9):1435-1441.
Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C. Long-term impact of
adherence to oral bisphosphonates on osteoporotic fracture incidence. Journal of bone and
mineral research : the official journal of the American Society for Bone and Mineral Research.
2012;27(1):202-210.
Ideguchi H, Ohno S, Takase K, Ueda A, Ishigatsubo Y. Outcomes after switching from one
bisphosphonate to another in 146 patients at a single university hospital. Osteoporos Int.
2008;19(12):1777-1783.
Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N. Factors contributing
to compliance with osteoporosis medication. Isr Med Assoc J. 2008;10(3):207-213.
Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adherence and occurrence of
fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiology and
drug safety. 2010;19(12):1233-1240.
Goldzweig CL, Balekian TM, Rolon C, Yano EM, Shekelle PG. The state of women veterans' health
research. Results of a systematic literature review. Journal of general internal medicine. 2006;21
Suppl 3:S82-92.
Yano EM, Hayes P, Wright S, et al. Integration of women veterans into VA quality improvement
research efforts: what researchers need to know. J Gen Intern Med. 2010;25 Suppl 1:56-61.
Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, Cram P. Testing and treatment for
osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos
Int. 2011;22(12):2973-2980.
Bass E, French DD, Bradham DD, Rubenstein LZ. Risk-adjusted mortality rates of elderly veterans
with hip fractures. Ann Epidemiol. 2007;17(7):514-519.
LaFleur J, Ginter T, Curtis J, et al. A novel method for obtaining bone mineral densities from a
dataset of radiology reports and clinic notes: Natural language processing in a national cohort of
postmenopausal veterans Paper presented at: Presented at the 2013 Annual Meeting of the
American Society for Bone and Mineral Research (ASBMR); October 4-7, 2013; Baltimore
Convention Center, Baltimore, Maryland.
De Silva L, Ginter T, Forbush T, et al. Extraction and Quantification of Pack-years and
Classification of Smoker Information in Semi-structured Medical Records: Workshop on Learning
from Unstructured Clinical Text. International Conference on Machine Learning (ICML); 2011;
Bellevue, WA.
Bellows BK, Lafleur J, Kamauu AW, et al. Automated identification of patients with a diagnosis of
binge eating disorder from narrative electronic health records. J Am Med Inform Assoc.
2014;21(e1):e163-168.
Manning C, Schutze H. Foundations of Statistical Natural Language Processing. Cambridge, MA:
MIT Press; 1999.
Kong SY, Kim DY, Han EJ, et al. Effects of a 'drug holiday' on bone mineral density and bone
turnover marker during bisphosphonate therapy. Journal of bone metabolism. 2013;20(1):31-35.
Soroko SB, Barrett-Connor E, Edelstein SL, Kritz-Silverstein D. Family history of osteoporosis and
bone mineral density at the axial skeleton: the Rancho Bernardo Study. J Bone Miner Res.
1994;9(6):761-769.
Robitaille J, Yoon PW, Moore CA, et al. Prevalence, family history, and prevention of reported
osteoporosis in U.S. women. Am J Prev Med. 2008;35(1):47-54.
de Lusignan S, Chan T, Wood O, Hague N, Valentin T, Van Vlymen J. Quality and variability of
osteoporosis data in general practice computer records: implications for disease registers. Public
Health. 2005;119(9):771-780.

15

ACCEPTED MANUSCRIPT

40.

41.

42.
43.

44.

45.
46.

47.
48.
49.

50.
51.
52.

PT

RI

SC

39.

NU

38.

MA

37.

36.

TE

35.

Cvijetic S, Colic Baric I, Satalic Z. Influence of heredity and environment on peak bone density: a
parent-offspring study. J Clin Densitom. 2010;13(3):301-306.
Wilson RA, Chapman WW, Defries SJ, Becich MJ, Chapman BE. Automated ancillary cancer
history classification for mesothelioma patients from free-text clinical reports. Journal of
pathology informatics. 2010;1:24.
Friedlin J, McDonald CJ. Using a natural language processing system to extract and code family
history data from admission reports. AMIA Annu Symp Proc. 2006:925.
Goryachev S, Kim H, Zeng-Treitler Q. Identification and extraction of family history information
from clinical reports. AMIA Annu Symp Proc. 2008:247-251.
Reggiardo MV, Fay F, Tanno M, et al. Natural history of hepatitis C virus infection in a cohort of
asymptomatic post-transfused subjects. Ann Hepatol. 2012;11(5):658-666.
Wu IC, Wu CC, Lu CY, et al. Substance use (alcohol, areca nut and cigarette) is associated with
poor prognosis of esophageal squamous cell carcinoma. PLoS One. 2013;8(2):e55834.
Casey R, Piazzon-Fevre K, Raverdy N, et al. Case-control study of lymphoid neoplasm in three
French areas: description, alcohol and tobacco consumption. European journal of cancer
prevention : the official journal of the European Cancer Prevention Organisation. 2007;16(2):142150.
Zhou X, Han H, Chankai I, Prestrud A, Brooks A. Approaches to text mining for clinical medical
records. Paper presented at: 2006 ACM Symposium on Applied Computing2006; Bourgogne
University, Dijon, France.
Uzuner O, Goldstein I, Luo Y, Kohane I. Identifying patient smoking status from medical
discharge records. J Am Med Inform Assoc. 2008;15(1):14-24.
McClung M, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in
subgroups of women with postmenopausal osteoporosis. Journal of bone and mineral research :
the official journal of the American Society for Bone and Mineral Research. 2011.
Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new
vertebral and hip fractures in postmenopausal women at high risk. The Journal of clinical
endocrinology and metabolism. 2011;96(6):1727-1736.
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of
Osteoporosis. Washington, D.C.: National Osteoporosis Foundation;2010.
Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis
and management of osteoporosis in Canada: summary. CMAJ : Canadian Medical Association
journal = journal de l'Association medicale canadienne. 2010;182(17):1864-1873.
Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis?
Journal of clinical epidemiology. 2011;64(1):46-53.
Kanis JA, Oden A, Johansson H, Borgstrm F, Strm O, McCloskey E. FRAX and its applications
to clinical practice. Bone. 2009;44(5):734-743.
Orr-Walker B, Wattie DJ, Evans MC, Reid IR. Effects of prolonged bisphosphonate therapy and its
discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf).
1997;46(1):87-92.
Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed
outcomes data. J Health Econ. 2005;24(3):465-488.
Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ.
2001;20(4):461-494.
Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using
generalized estimating equations: an orientation. American journal of epidemiology.
2003;157(4):364-375.

AC
CE
P

34.

16

ACCEPTED MANUSCRIPT

59.

60.

61.
62.

63.

64.

65.
66.
67.

PT

RI

SC

58.

NU

57.

MA

56.

55.

TE

54.

De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcareassociated infections on length of stay and costs. Clin Microbiol Infect. 2010;16(12):1729-1735.
Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on
pharmaceutical and medical utilization and expenditures. The American journal of managed care.
2009;15(2):123-131.
Yun H, Curtis JR, Guo L, et al. Patterns and predictors of osteoporosis medication discontinuation
and switching among Medicare beneficiaries. BMC Musculoskelet Disord. 2014;15(1):112.
Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with intravenous zoledronate and
intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken).
2012;64(7):1054-1060.
Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6
chronic medication classes. Journal of managed care pharmacy : JMCP. 2009;15(9):728-740.
Cotte FE, Cortet B, Lafuma A, et al. A model of the public health impact of improved treatment
persistence in post-menopausal osteoporosis in France. Joint Bone Spine. 2008;75(2):201-208.
Richardson KK, Cram P, Vaughan-Sarrazin M, Kaboli PJ. Fee-based Care is Important for Access
to Prompt Treatment of Hip Fractures Among Veterans. Clinical orthopaedics and related
research. 2013;471(3):1047-1053.
Fleming C, Fisher ES, Chang CH, Bubolz TA, Malenka DJ. Studying outcomes and hospital
utilization in the elderly. The advantages of a merged data base for Medicare and Veterans
Affairs hospitals. Med Care. 1992;30(5):377-391.
Lee YK, Nho JH, Ha YC, Koo KH. Persistence with intravenous zoledronate in elderly patients with
osteoporosis. Osteoporos Int. 2012;23(9):2329-2333.
Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more
important than frequency of dosing of anti-osteoporosis treatments in determining patient
adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int.
2011;22(3):741-753.
Nelson S, Del Fiol G, Hanseler H, Crouch B, Cummins M. A dashboard for health information
exchange between poison control centers and emergency departments: The poison control
center view. Poster presented at 2014 Annual Meeting of the North American Congress of
Clinical Toxicology (NACCT); October 17-21, 2014; Sheraton New Orleans Hotel, New Orleans, LA.
Weeks WB, Wallace AE, Wang S, Lee A, Kazis LE. Rural-urban disparities in health-related quality
of life within disease categories of Veterans. The Journal of rural health : official journal of the
American Rural Health Association and the National Rural Health Care Association.
2006;22(3):204-211.
Weeks WB, Kazis LE, Shen Y, et al. Differences in health-related quality of life in rural and urban
veterans. Am J Public Health. 2004;94(10):1762-1767.
Mackenzie TA, Wallace AE, Weeks WB. Impact of rural residence on survival of male veterans
affairs patients after age 65. J Rural Health. 2010;26(4):318-324.
Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR. Effect of
alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the
Fracture Intervention Trial. Journal of bone and mineral research : the official journal of the
American Society for Bone and Mineral Research. 2012;27(8):1804-1810.

AC
CE
P

53.

17

ACCEPTED MANUSCRIPT
FIGURE LEGENDS
Figure 1. Attrition summary for study sample

PT

Figure 2. Percentages of patients classified as non-switchers, discontinuers, switchers, and reinitiators in

each quarter following the index date

AC
CE
P

TE

MA

NU

SC

RI

Figure 3. Unadjusted (a) and adjusted (b) risks of hip and any major fracture associated with timevarying quarterly bisphosphonate exposure and patient baseline risk

18

ACCEPTED MANUSCRIPT

AC
CE
P

TE

MA

NU

SC

RI

PT

Figure 1. Attrition summary for study sample

19

ACCEPTED MANUSCRIPT

AC
CE
P

TE

MA

NU

SC

RI

PT

Figure 2. Percentages of patients classified as non-switchers, discontinuers, switchers, and reinitiators in each
quarter following the index date

20

ACCEPTED MANUSCRIPT

Figure 3. Unadjusted (a) and adjusted (b) risks of hip and any major fracture associated with time-varying quarterly bisphosphonate exposure and patient
baseline risk
1.69
(a) Unadjusted

PT

3.00
2.50

1.08
1.12 1.03 0.93 1.01 1.14 1.08 1.2 0.94 1.01

SC

1.11

1.00

RE

NCE

SW
CCSW CQNP

RE

NCE

OVERALL

SW
CCSW CQNP

RE

NCE

SW

CCSW CQNP

HIGH-RISK*

NOT HIGH-RISK

ANY MAJOR FRACTURE

(b) Adjusted

CE

3.00
2.50

0.94

0.91 1.02

SW
CCSW CQNP

RE

NCE

OVERALL

1.21

0.83 1.01

SW
CCSW CQNP

RE

NCE

HIGH-RISK*

CCSW CQNP

NOT HIGH-RISK

HIP FRACTURE
1.28
0.79

1.44
1.29

0.95

AC

2.00

RE

NCE

PT
ED

SW

MA

0.50

1.50

0.9 1.01

NU

1.50

0.00

0.82

1.46

1.38

2.00
1.17 1.08 1.16 0.96 1.01

1.6

RI

1.22

0.95 0.98 1.05 0.89 1.00 0.85 0.95 0.90 0.88 0.99 1.07 1.01 1.14 0.92 1.00

1.26

1.21

0.82 1.01

1.02

0.83 1.02

0.82 1.01

0.92

1.00
0.50
0.00

SW

RE

NCE

SW
CCSW CQNP

OVERALL

D
NCE

RE

SW
CCSW CQNP

HIGH-RISK*
ANY MAJOR FRACTURE

D
NCE

RE

SW
CCSW CQNP

NOT HIGH-RISK

RE

NCE

SW
CCSW CQNP

OVERALL

D
NCE

RE

SW
CCSW CQNP

HIGH-RISK*

D
NCE

RE
CCSW CQNP

NOT HIGH-RISK

HIP FRACTURE

Key: SW = Switching; D = Discontinuing; RE = Reinitiating; NCE = Non-cumulative exposure (Ref: Non-switching); CCSW = Cumulative count of switches (Ref: None); CQNP =
Cumulative quarters of discontinuation (Ref: None). *High-risk defined as 2 or more of the following: (1) femoral neck T-score -2.5; (2) age 70 and total hip, spine, or onethird radius T-score -2.5; (3) prior fracture of hip, spine, one-third radius, humerus, pelvis, or tibia/fibula.

21

ACCEPTED MANUSCRIPT
Table 1. Frequencies and percentages for selected baseline patient characteristics in N=35,650 patients who met
all inclusion/exclusion criteria
%

6,657
6,856
5,771
3,636
2,543
1,786
5,397
3,004

18.7
19.2
16.2
10.2
7.1
5.0
15.1
8.4

319
3,122
26,645
483
459
4,622

0. 9
8.8
74.7
1.4
1.3
13.0

20.4
19.6
15.6
9.9
7.2
4.8
14.8
7.6

79
438
5,012
58
89
1,128

1.2
6.4
73.7
0.9
1.3
16.6

240
2,684
21,633
425
370
3,494

0.8
9.3
75.0
1.5
1.3
12.1

3.5
35.2
31.2
16.4
6.7
3.5
3.4

282
2,511
2,047
1,037
413
248
266

4.1
36.9
30.1
15.2
6.1
3.6
3.9

976
10,024
9,076
4,825
1,985
997
963

3.4
34.8
31.5
16.7
6.8
3. 5
3.3

9,303
14,513
4,544
6,936
354

26.1
40.7
12.7
19. 5
1.0

1,514
2,944
786
1,486
74

22.3
43.3
11.6
21.8
1.9

7,789
11,569
3,758
5,450
280

27.0
40.1
13.0
18.9
1.0

9,888
6,253
10,463
9,046

27.7
17.5
29.3
25.4

1,942
1,165
3,697
1,915

28.5
17.1
54.3
28.1

7,946
5,088
15,812
7,131

27.5
17.6
54.8
24.7

4,742
3,145
1,911
25,852

13.3
8.8
5.4
72.5

932
603
409
4,860

13.7
8.9
6.0
71.4

3,810
2,542
1,502
20,992

13.2
8.8
5.2
72.8

10,012
8,183
8,792
8,663

28.1
23.0
24.7
24.3

1,901
1,459
1,701
1,743

27.9
21.4
25.0
25.6

8,111
6,724
7,091
6,920

28.1
23.3
24.6
24.0

MA
D

TE

RI

5,888
5,652
4,497
2,845
2,085
1,393
4,284
2,202

NU

11.3
17.7
18.7
11.6
6.7
5.8
16.4
11.8

1,258
12,535
11,123
5,862
2,398
1,245
1,229

769
1,204
1,274
791
458
393
1,113
802

Change cohort
(N=28,846)
N
%

SC

AC
CE
P

DEMOGRAPHICS
Age
<55
55-59
60-64
65-69
70-74
75-79
80-84
85+
Race/ethnicity
Asian
Black
Caucasian
Hispanic
Other
Unknown
BMI (NIH classification)
Underweight (<18.5)
Normal (18.5-24.9)
Overweight (25.0-29.9)
Obesity class 1 (30.0-34.9)
Obesity class 2 (35.0-39.9)
Extreme obesity (40.0+)
Unknown
Marital status
Divorced
Married
Never married/single
Widowed
Unknown
Smoking status
Current
Former
Never
Unknown
Alcohol history
Current
Past
Never
Unknown
Healthcare visit frequency in
prior year
<5
5-9
10-19
>19

Non-switching cohort
(N=6,804)
N
%

PT

Overall
(N=35,650)

22

ACCEPTED MANUSCRIPT
Table 1. Frequencies and percentages for selected baseline patient characteristics in N=35,650 patients who met
all inclusion/exclusion criteria
Overall
(N=35,650)

Non-switching cohort
(N=6,804)
N
%

Change cohort
(N=28,846)
N
%

AC
CE
P

TE

MA

NU

SC

RI

PT

N
%
DISEASE CHARACTERISTICS
a
High risk
Yes
5,478
15.4
1,079
15.9
4,399
15.2
No
30,172
84.6
5,725
84.1
24,447
84.8
b
FRAX score (hip)
19,337
54.2
3,265
48.0
16,072
55.7
3%
<3%
11,232
31.5
2,322
34.1
8,910
30.9
Unknown
5,801
14.3
1,217
17.9
3,864
13.4
b
FRAX score (any major fracture)
24,808
69.6
4,336
63.7
20,472
71.0
20%
<20%
5,761
16.2
1,251
18.4
4,150
15.6
Unknown
5,081
14.3
1,217
17.9
3,864
13.4
Lowest T-score (WHO criteria)
Normal T-score (above -1.0)
4,632
13.0
685
10.1
3,947
13.7
Low bone mass (-1.0 to -2.5)
10,881
30.5
1,795
26.4
9,086
31.5
Osteoporosis (below -2.5)
7,032
19.7
1,265
18.6
5,767
20.0
Missing
13,105
36.8
3,059
45.0
10,046
34.8
Prior fracture
Forearm
636
1.8
124
1.8
512
1.8
Hip
335
0.9
84
1.2
251
0.9
Humerus
363
1.0
82
1.2
281
1.0
Spine
555
1.6
114
1.7
441
1.5
c
Other
2,764
7.8
573
8.4
2,191
7.6
Major fracture
2,855
8.0
361
5.3
2,494
8.6
Family/maternal history of
4,614
12.9
866
12.7
3,748
13.0
osteoporosis
Family/maternal history of
2,005
5.6
397
5.8
1,608
5.6
fracture
Index bisphosphonate
Alendronate
32,971
92.5
6,252
91.9
26,719
92.6
Ibandronate
78
0.2
24
0.4
54
0.2
Risedronate
2,261
6.4
343
5.0
1,918
6.6
Zoledronic acid
340
1.0
185
2.7
155
0.5
Patient switching categories were characterized over the entire observation period in the descriptive analysis. Also
descriptively characterized comorbidities and concomitant drug exposures.
Key: BMI body mass index; NIH - National Institutes of Health; WHO World Health Organization.
a. Defined as 2 or more of the following: (1) femoral neck T-score -2.5; (2) age 70 and total hip, spine, or one-third radius
T-score -2.5; (3) prior fracture of the hip, spine, one-third radius, humerus, pelvis, or tibia/fibula.
b. FRAX score calculated using BMD at the femoral neck, total hip, spine, or 1/3 radius if BMD was known and BMI if BMD
was not known
c. Excluding head, face, hands, and feet.

23

ACCEPTED MANUSCRIPT
Table 2. Significant predictors of discontinuation at p<0.1
N

Events

Ia

Univariate (unadjusted) Multivariable (adjusted)

HR
95% CI
HR
95% CI

AC
CE
P

TE

MA

NU

SC

RI

PT

DEMOGRAPHICS
Age
<55
9,858
8,535
45.4
Ref
Ref
55-64
10,859
8,409
43.4
0.87
0.85, 0.90
0.91
0.88, 0.95
65-74
5,136
4,163
16.6
0.74
0.72, 0.77
0.84
0.81, 0.88
75-84
7,577
5,924
20.8
0.64
0.62, 0.67
0.79
0.75, 0.83
85+
2,220
1,592
8.3
0.81
0.77, 0.86
0.78
0.75, 0.82
Race/ethnicity
Caucasian
26,645
21,456
95.3
Black
3,075
2,622
16.2
1.37
1.32, 1.43
1.17
1.12, 1.22
Hispanic
530
469
2.4
1.26
1.15, 1.38
1.21
1.10, 1.32
Other
778
603
2.9
1.04
0.95, 1.12
0.99
0.91, 1.07
Unknown
4,622
3,473
14.9
0.91
0.88, 0.94
1.00
0.97, 1.04
Marital status
Married
14,513
11,458
49.8
Ref
Ref
Not married
21,137
17,165
80.7
1.10
1.07, 1.12
1.08
1.05, 1.10
Smoking status
Current
10,463
8,621
42.7
Ref
Ref
Former
6,253
5,050
24.0
0.95
0.92, 0.98
0.98
0.95, 1.02
Never
9,888
7,882
34.0
0.87
0.84, 0.89
0.93
0.90, 0.96
Unknown
9,046
7,070
30.3
0.84
0.82, 0.87
0.92
0.89, 0.95
Healthcare visit frequency
Visits in prior year <5
10,012
8,062
26.6
Ref
Ref
Visits in prior year 5-9
8,183
6,677
31.2
1.36
1.32, 1.41
1.23
1.19, 1.27
Visits in prior year 10-19
8,792
7,036
38.6
1.52
1.47, 1.57
1.22
1.18, 1.27
Visits in prior year >19
8,663
6,848
41.1
1.61
1.55, 1.66
1.11
1.06, 1.16
DISEASE CHARACTERISTICS
Index bisphosphonate
Alendronate
32,971
26,571
120.3
Ref
Ref
Ibandronate
78
52
0.3
1.00
0.76, 1.31
0.86
0.67, 1.14
Risedronate
2,261
1,845
8.7
1.05
1.00, 1.10
1.07
1.02, 1.12
Zoledronic acid
340
155
0.9
0.68
0.58, 0.79
0.58
0.49, 0.68
COMORBIDITIES (VERSUS NONE)
Depression diagnosis
5,803
4,705
31.3
1.41
1.37, 1.46
1.10
1.06, 1.14
OTHER DRUG EXPOSURES (VERSUS NONE)
Calcitonin
823
677
3.7
1.18
1.09, 1.27
1.10
1.02, 1.19
Calcium
7,258
5,677
36.5
1.33
1.29, 1.37
1.06
1.03, 1.10
Heparin
1,180
897
6.9
1.43
1.34, 1.53
1.13
1.05, 1.21
Benzodiazepines
5,645
4,504
27.7
1.30
1.26, 1.34
1.04
1.01, 1.08
Opioids
12,014
9,625
60.6
1.43
1.39, 1.47
1.15
1.11, 1.18
Corticosteroids
4,244
3,373
98.3
1.42
1.35, 1.41
1.13
1.05, 1.13
Thiazide diuretics
8,414
6,627
22.3
1.13
1.10, 1.16
1.03
1.00, 1.06
Vitamin D
11,219
8,941
34.9
1.33
1.29, 1.36
1.09
1.06, 1.13
a. Incidence of discontinuation per 1,000 person-years
Key: HR Hazard ratio; CI Confidence interval; Ref reference; NS Not significant; BMI body mass index; NIH - National
Institutes of Health

24

ACCEPTED MANUSCRIPT
Table 3. Unadjusted and adjusted percentage differences in quarterly total and osteoporosis-related costs
associated with change behaviors compared to non-switchers

AC
CE
P

TE

MA

NU

SC

RI

PT

Univariate (unadjusted)
Multivariable (adjusted)a
Percentage
Absolute
Percentage
Absolute
Stratum
95% CI
95% CI
95% CI
95% CI
difference
differenceb
difference
differenceb
TOTAL COST DIFFERENCES
Overall (Reference = Non-switching)
Switching
0.14
0.06, 0.22
331.40
147.87, 514.3
0.14
0.06, 0.21
317.55
140.05, 495.04
Discontinuing
0.02
0.00, 0.05
51.73
-6.41, 109.87
0.05
0.03, 0.08
123.13
66.90, 179.37
Reinitiating
0.10
0.07, 0.14
242.55
158.35, 326.75
0.17
0.13, 0.20
393.62
311.71, 475.53
High-risk (Reference = Non-switching)
Switching
0.06
-0.14, 0.25
186.95
-476.60, 850.51
0.13
-0.07, 0.33
424.39 -223.60, 1072.38
Discontinuing
0.03
-0.04, 0.10
97.19
-142.19, 336.57
0.08
0.01, 0.15
267.72
33.56, 501.98
Reinitiating
0.09
-0.01, 0.19
304.27
-31.42, 639.97
0.20
0.10, 0.30
637.19
307.42, 966.95
Not high-risk (Reference = Non-switching)
Switching
0.16
0.08, 0.23
343.71
170.23, 517.18
0.14
0.06, 0.21
294.07
127.40, 460.73
Discontinuing
0.02
-0.00, 0.05
46.79
-6.72, 100.31
0.05
0.02, 0.07
102.38
50.96, 153.80
Reinitiating
0.10
0.07, 0.14
221.45
143.65, 299.25
0.16
0.12, 0.19
342.64
267.45, 417.83
OSTEOPOROSIS-RELATED COST DIFFERENCES
Overall (Reference = Non-switching)
Switching
-0.01
-0.18, 0.15
-1.05
-12.66, 10.56
-0.14
-0.29, 0.00
-10.42
-21.07, 0.22
Discontinuing
-0.92
-1.01, -0.82
-64.19
-70.66, -57.71
-1.06
-1.14, -0.98
-77.12
-82.85, -71.40
Reinitiating
-0.18
-0.32, -0.04
-12.82
-22.39, -3.26
-0.22
-0.32, -0.11
-15.62
-23.42, -7.83
High-risk (Reference = Non-switching)
Switching
0.30
-0.07, 0.67
35.28
-8.96, 79.53
0.30
-0.14, 0.73
36.07
-17.57, 89.71
Discontinuing
-0.45
-0.66, -0.24
-53.25
-78.22, -28.29
-0.63
-0.79, -0.47
-76.40
-95.40, -57.40
Reinitiating
-0.19
-0.46, 0.08
-22.38
-54.63, 9.87
-0.17
-0.39, 0.04
-21.25
-46.94, 4.44
Not high-risk (Reference = Non-switching)
Switching
-0.19
-0.34, -0.05
-11.91
-20.95, -2.88
-0.27
-0.40, -0.15
-17.22
-24.95, -9.48
Discontinuing
-1.08
-1.18, -0.98
-66.12
-72.31, -59.94
-1.18
-1.26, -1.09
-73.94
-79.36, -68.52
Reinitiating
-0.19
-0.35, -0.03
-11.60
-21.29, -1.90
-0.24
-0.36, -0.12
-14.82
-22.18, -7.46
OSTEOPOROSIS-RELATED PHARMACY COST DIFFERENCES
Overall (Reference = Non-switching)
Switching
-0.76
-0.88, -0.65
-24.48
-28.27, -20.69
-0.66
-0.78, -0.54
-21.35
-24.22, -17.48
Discontinuing
-2.35
-2.38, -2.32
-75.40
-77.04, -73.76
-2.34
-2.37, -2.31
-75.14
-76.57, -73.71
Reinitiating
-0.59
-0.61, -0.56
-18.78
-19.74, -17.83
-0.58
-0.61, -0.56
-18.80
-19.65, -17.95
High-risk (Reference = Non-switching)
Switching
-0.61
-1.05, -0.17
-20.75
-35.61, -5.89
-0.61
-0.98, -0.24
-20.73
-33.19, -8.27
Discontinuing
-2.22
-2.31, -2.13
-75.71
-81.44, -69.98
-2.20
-2.28, -2.11
-75.07
-79.61, -70.53
Reinitiating
-0.61
-0.68, -0.53
-20.62
-23.84, -17.40
-0.60
-0.66, -0.54
-20.39
-22.92, -17.87
Not high-risk (Reference = Non-switching)
Switching
-0.81
-0.89, -0.73
-25.59
-28.14, -23.04
-0.67
-0.79, -0.56
-21.46
-25.04, -17.89
Discontinuing
-2.38
-2.41, -2.34
-75.31
-76.95, -73.68
-2.36
-2.40, -2.33
-75.21
-76.62, -73.79
Reinitiating
-0.58
-0.61, -0.56
-18.47
-19.45, -17.49
-0.58
-0.61, -0.56
-18.54
-19.41, -17.67
a Adjusted for demographics (age, marital status, race, visits in the prior year), bisphosphonate, FRAX risk factors (alcohol
exposure, BMI, prior fracture with site, rheumatoid arthritis, secondary osteoporosis, smoking status, and corticosteroid use),
other drug exposures (calcitonin, calcium, heparin, hormone therapy, proton pump inhibitors, raloxifene, benzodiazepines,
opioids, somnolence-causing drugs, selective serotonin reuptake inhibitors, statins, teriparatide, thiazide diuretics, thyroid
medications, vitamin D), comorbid conditions (COPD and depression), and 6 months of cost prior to index date.
b In 2011 dollars.

25

ACCEPTED MANUSCRIPT
HIGHLIGHTS

PT

Persistence with bisphosphonates is frequently poor, and stopping, restarting, or switching

bisphosphonates is common.

SC

RI

We evaluated bisphosphonate change behaviors, fractures and costs in a large, national cohort of
postmenopausal veterans.

MA

NU

Most patients discontinue treatment at some point, which did not significantly increase fracture risk in
the majority of patients.

AC
CE
P

TE

Bisphosphonate change behaviors were associated with significantly lower osteoporosis costs, but
significantly higher total costs.

26